Amlodipine Cost in Washington 2026: Cash Price, Medicaid, and Savings Options

What Does Amlodipine Actually Cost in Washington in 2026?

Generic amlodipine is one of the least expensive prescription drugs available in Washington state. The average retail cash price sits at roughly $8 per month for a 30-tablet supply in 2026, a figure driven by intense generic competition following patent expiration. Pfizer's brand-name Norvasc carries a manufacturer list price near $80 per month, but the brand version is rarely necessary.

Amlodipine belongs to the dihydropyridine calcium channel blocker class and received FDA approval for hypertension and angina. The FDA-approved prescribing information, available through the FDA's drug database at accessdata.fda.gov, confirms the approved dose range of 2.5 mg to 10 mg once daily for adults. Multiple generic manufacturers now produce the tablet, which is why the Washington cash price has dropped so far below the brand list price.

Price variation across Washington pharmacies is real. A 5 mg, 30-tablet supply ranges from roughly $4 at warehouse-style pharmacies (Costco, Sam's Club) to around $14 at some independent drugstores without discount programs. Requesting a 90-day supply instead of 30 days often reduces the per-tablet cost further, typically landing near $12 to $18 for three months rather than $24 for three separate monthly fills.

Discount coupon platforms such as GoodRx, RxSaver, and NeedyMeds aggregate pricing from Washington pharmacies in real time. Applying a free coupon from one of those platforms at checkout routinely brings the 30-day price below $5 at major chains like Walgreens, Rite Aid, and Fred Meyer locations across Seattle, Spokane, and Tacoma. NCBI's drug pricing overview notes that generic drug prices vary substantially by dispensing channel, reinforcing the value of comparing at the point of sale rather than assuming a standard price.

Does Washington Medicaid (Apple Health) Cover Amlodipine?

Washington Apple Health covers generic amlodipine, but a prior authorization (PA) is required before the plan will pay. This means the prescribing clinician must submit documentation showing that amlodipine is appropriate for the patient's condition before the pharmacy claim processes.

The Washington State Health Care Authority (HCA) publishes the Apple Health Preferred Drug List (PDL), which classifies antihypertensives by tier and PA requirements. Calcium channel blockers as a class are generally covered under Apple Health managed care plans (Amerigroup, Community Health Plan of Washington, Coordinated Care, Molina, and United Healthcare Community Plan), but individual plan formularies may impose different cost-sharing rules. Patients enrolled in Apple Health should ask their prescriber's office to submit the PA before presenting the prescription at the pharmacy. PA turnaround times in Washington average one to three business days for non-urgent requests.

For Apple Health clients who qualify, approved amlodipine coverage brings the out-of-pocket cost to $0 or a nominal copay under $5 for most managed care plan enrollees. The Centers for Medicare and Medicaid Services requires state Medicaid programs to cover medications that are "medically necessary," and amlodipine's position on multiple national hypertension guidelines makes the PA approval rate high when submitted correctly.

If a PA is denied, the prescriber can appeal or switch the patient to a comparable covered agent. Thiazide diuretics such as chlorthalidone 25 mg daily appear on Washington's PDL without PA requirements, though clinical factors determine whether a switch is appropriate.

How Does Washington Private Insurance Cover Amlodipine?

Most commercial plans in Washington place generic amlodipine on Tier 1 (preferred generic), resulting in a copay between $0 and $15 per month depending on the specific plan design. Washington state insurers regulated by the Washington State Office of the Insurance Commissioner (OIC) must comply with ACA cost-sharing rules, and a Tier 1 generic like amlodipine typically falls well within standard formulary coverage.

Plans purchased through Washington Healthplanfinder (the state exchange) follow the same formulary transparency rules. Before enrolling or during open enrollment, patients can use the Healthplanfinder plan comparison tool to check which tier amlodipine occupies on a specific Qualified Health Plan (QHP).

Medicare Part D plans available to Washington beneficiaries also cover amlodipine. The CMS Medicare drug coverage data shows amlodipine on virtually all Part D formularies at the lowest cost-sharing tier. The standard Part D deductible in 2026 is $590 before coverage kicks in for Tier 1 drugs at many plans, but some plans waive the deductible for preferred generics. Low-Income Subsidy (LIS or "Extra Help") recipients pay $0 to $4.50 per fill for generics covered at Tier 1.

Employer-sponsored plans in Washington follow similar patterns. A 2024 Kaiser Family Foundation employer benefits survey found that 90% of covered workers had access to a Tier 1 generic tier with a median copay of $11. Amlodipine's inclusion in that tier is standard across Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and most other major Washington carriers.

Is Compounded Amlodipine Legal in Washington?

Compounded amlodipine is legal in Washington when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The FDA's guidance on compounding distinguishes between 503A patient-specific compounding pharmacies and 503B outsourcing facilities. Washington state requires compounding pharmacies to hold a Washington State Department of Health pharmacy license and comply with USP <795> standards for non-sterile preparations.

Amlodipine compounded oral solutions or alternative dose-strength tablets are prepared at 503A pharmacies when a licensed prescriber writes a prescription citing a clinical need (for example, a patient who cannot swallow standard tablets and needs an oral liquid, or a pediatric patient needing a 1 mg dose not commercially available). The state does not prohibit 503A compounding of commercially available drugs per se, but pharmacists must document clinical rationale when compounding a drug available in an FDA-approved form.

Some HealthRX telehealth patients in Washington have accessed compounded amlodipine formulations at $0 out-of-pocket cost through pharmacy partnerships included in their care plan. Eligibility depends on clinical qualification, insurance status, and the specific pharmacy relationship. Patients interested in this pathway should discuss it directly with their HealthRX prescriber during their intake visit.

What Evidence Supports Using Amlodipine for Hypertension?

Amlodipine's clinical track record is one of the most thoroughly documented in cardiovascular medicine. The ASCOT-BPLA trial, published in The Lancet in 2005, randomized 19,257 patients with hypertension to either an amlodipine-based regimen or an atenolol-based regimen. The amlodipine group showed a 23% relative risk reduction in non-fatal myocardial infarction and fatal coronary heart disease compared to the atenolol group (P<0.001). The trial was stopped early at a median follow-up of 5.5 years because the benefit in the amlodipine arm was already statistically definitive. ASCOT-BPLA full text is available on PubMed.

The ALLHAT trial (N=33,357), one of the largest antihypertensive outcome trials ever conducted, found that chlorthalidone, amlodipine, and lisinopril produced similar rates of the primary combined outcome of fatal coronary heart disease or non-fatal MI. This positioned calcium channel blockers alongside thiazides and ACE inhibitors as first-line agents. The ALLHAT results are indexed on PubMed.

The 2022 ACC/AHA Hypertension Guideline, available through the American Heart Association, lists thiazide-type diuretics, ACE inhibitors, ARBs, and calcium channel blockers (including amlodipine) as first-line drug classes for most adults with stage 1 or stage 2 hypertension. The guideline states: "Initiation of antihypertensive drug therapy with agents from any of the four first-line drug classes is recommended." Amlodipine is the most prescribed representative of its class in the United States.

For chronic stable angina, amlodipine reduces the frequency of anginal episodes and increases exercise tolerance. A randomized controlled trial published in The Lancet demonstrated that amlodipine 10 mg daily significantly reduced angina frequency compared to placebo over 8 weeks.

Can You Get an Amlodipine Prescription via Telehealth in Washington?

Telehealth prescribing of amlodipine is fully legal in Washington state. The Washington State Medical Commission allows licensed physicians and advanced practice providers (APRNs, PAs) to prescribe non-controlled medications after a synchronous audio-video encounter that satisfies the standard of care for an in-person visit. Amlodipine is a non-controlled substance, which removes the additional DEA telemedicine prescribing restrictions that apply to controlled medications.

Washington's telehealth parity law (RCW 74.09.325) requires insurers regulated by the OIC to reimburse telehealth-delivered services at parity with in-person care. For hypertension management, this means an insured patient can receive a blood pressure evaluation, amlodipine prescription, and follow-up monitoring entirely through telehealth without additional cost barriers beyond their standard office visit cost-sharing.

HealthRX prescribers licensed in Washington can evaluate patients for hypertension or angina via video visit, order baseline labs if needed (typically a basic metabolic panel to check potassium and renal function), and send an amlodipine prescription electronically to any Washington retail or mail-order pharmacy. Most patients in Washington have the prescription filled within the same business day. Follow-up visits to titrate the dose from 5 mg to 10 mg or to assess tolerability (ankle edema is the most common side effect, reported in approximately 10% of patients at 10 mg in the amlodipine FDA label) are also completed via telehealth.

What Savings Programs Apply to Amlodipine in Washington?

Several layered savings options are available to Washington residents.

Generic discount programs. Washington's major pharmacy chains participate in $4 and $10 generic programs. Fred Meyer's generic program and Walmart's $4 generics list include amlodipine 5 mg and 10 mg. Costco Pharmacy in Washington typically prices a 90-day supply of amlodipine at under $10 without any membership-based additional discount beyond their standard low pricing.

Pfizer patient assistance. Pfizer operates the Pfizer RxPathways program for brand-name Norvasc. Patients with household income below 400% of the federal poverty level who lack insurance coverage for the drug may qualify for free or reduced-cost branded product. The application is available through Pfizer's patient assistance website. For most Washington patients, however, the $8 generic cash price makes the brand assistance program unnecessary.

Washington State Prescription Drug Program. Washington's Prescription Drug Program, administered through the HCA, negotiates supplemental rebates from manufacturers and publishes preferred pricing that participating pharmacies must honor. Uninsured and underinsured Washington residents can check the program's participating pharmacy list to access negotiated pricing.

NeedyMeds and RxAssist. Both platforms list patient assistance programs applicable in Washington. NeedyMeds maintains a current database of state pharmaceutical assistance programs, and their drug information page on amlodipine is updated regularly.

340B pharmacies. Federally Qualified Health Centers (FQHCs) and other 340B-covered entities in Washington (including community health centers in Seattle, Yakima, and Spokane) dispense amlodipine to qualifying low-income patients at 340B acquisition cost, which is frequently under $2 for a 30-day supply.

How Does Amlodipine Dosing Work, and What Affects Cost?

Amlodipine is available in three strengths: 2.5 mg, 5 mg, and 10 mg tablets. All three strengths are available as generics and carry nearly identical cash prices in Washington. The FDA-approved starting dose for hypertension in adults is 5 mg once daily, with uptitration to 10 mg once daily after 7 to 14 days if blood pressure remains above target. The 2.5 mg tablet is used primarily in elderly patients, small adults, or patients with hepatic impairment, where slower titration reduces the risk of excessive vasodilation and edema.

Because all three strengths cost approximately the same per-tablet in Washington, there is no meaningful cost difference between starting at 5 mg versus titrating to 10 mg. Tablet splitting is not recommended for amlodipine because the tablets are film-coated and splitting may affect dissolution rate, though some pharmacists do advise splitting 10 mg tablets to achieve a 5 mg dose as a cost measure. The FDA label does not specifically prohibit splitting, but patients should discuss this with their pharmacist before doing so.

Drug interactions that affect amlodipine metabolism are relevant to dosing. CYP3A4 inhibitors (including clarithromycin, ketoconazole, and grapefruit juice in large quantities) can increase amlodipine plasma concentrations by up to 56%, according to pharmacokinetic data in the FDA label. Patients on these agents may need a lower amlodipine dose, which could incidentally affect which tablet strength is prescribed and therefore the specific pharmacy SKU cost.

A 2023 systematic review indexed on PubMed confirmed that once-daily amlodipine achieves 24-hour blood pressure control with trough-to-peak ratios above 0.7, meeting FDA criteria for adequate antihypertensive effect across the dosing interval. This pharmacokinetic profile supports high adherence rates because patients experience no dosing-time dependency.

Amlodipine Side Effects and What to Watch for in Washington Patients

Peripheral edema is the most frequently reported side effect. In clinical trials, ankle or foot edema occurred in approximately 10.8% of patients receiving 10 mg daily compared to 1.8% on placebo, as listed in the FDA prescribing information. The edema is dose-dependent and results from arteriolar dilation without corresponding venodilation, not from fluid retention in the classic sense.

Flushing occurred in 2.6% of patients in controlled trials and is more common in women and during the first weeks of therapy. Palpitations were reported in 4.5% of patients on 10 mg. These are self-limited for most patients and rarely require discontinuation.

Washington patients receiving telehealth prescriptions for amlodipine should plan a follow-up video visit 4 to 6 weeks after initiation to assess blood pressure response and edema. The JNC 8 guideline recommends a monthly follow-up until blood pressure is controlled, then every 3 to 6 months for stable patients. Home blood pressure monitors meeting the American Heart Association validation criteria are available at most Washington pharmacies for $25 to $50 and allow patients to submit readings through HealthRX's patient portal between visits.

Comparing Amlodipine to Similar Medications in Washington

Amlodipine's Washington cash price of approximately $8 per month places it in the same cost tier as other first-line generics. Lisinopril 10 mg costs roughly $4 to $7 per month. Losartan 50 mg runs approximately $8 to $12. Chlorthalidone 25 mg averages around $6. None of these agents has a meaningful cost advantage over amlodipine at the generic level.

The choice among first-line agents depends on clinical factors, not cost. Amlodipine is preferred when the patient has concurrent chronic stable angina, when an ACE inhibitor causes cough, or when hyperkalemia limits ARB or ACE use. The 2017 ACC/AHA guideline notes that Black patients respond better to calcium channel blockers and thiazide diuretics than to ACE inhibitors as monotherapy, a finding that influenced guideline-based selection of amlodipine as a preferred first-line option in that population.

Patients with heart failure with reduced ejection fraction (HFrEF) should generally avoid amlodipine because calcium channel blockers can worsen ventricular function in that setting, though amlodipine specifically showed neutral mortality effects in the PRAISE-2 trial. Patients with known HFrEF should discuss this distinction with their cardiologist before starting amlodipine.